Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $81.50.

Several research analysts have weighed in on RARE shares. Canaccord Genuity Group reduced their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Cantor Fitzgerald reiterated an "overweight" rating and set a $105.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, September 5th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday. Guggenheim reiterated a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Finally, Morgan Stanley reduced their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, July 14th.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $31.45 on Friday. The stock has a fifty day moving average of $29.75 and a 200-day moving average of $33.06. The stock has a market capitalization of $3.03 billion, a P/E ratio of -5.69 and a beta of 0.21. Ultragenyx Pharmaceutical has a 52 week low of $25.81 and a 52 week high of $57.99.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The company had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. During the same period last year, the firm earned ($1.52) EPS. The business's revenue for the quarter was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,450 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the transaction, the executive vice president directly owned 73,271 shares of the company's stock, valued at approximately $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in RARE. GAMMA Investing LLC increased its position in Ultragenyx Pharmaceutical by 6,279.5% during the first quarter. GAMMA Investing LLC now owns 27,049 shares of the biopharmaceutical company's stock worth $979,000 after buying an additional 26,625 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Ultragenyx Pharmaceutical by 211.7% during the first quarter. Assenagon Asset Management S.A. now owns 215,890 shares of the biopharmaceutical company's stock worth $7,817,000 after buying an additional 146,617 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in Ultragenyx Pharmaceutical by 19.7% during the first quarter. Oppenheimer Asset Management Inc. now owns 7,140 shares of the biopharmaceutical company's stock worth $259,000 after buying an additional 1,173 shares during the last quarter. Peregrine Capital Management LLC increased its position in Ultragenyx Pharmaceutical by 3.4% during the first quarter. Peregrine Capital Management LLC now owns 169,467 shares of the biopharmaceutical company's stock worth $6,136,000 after buying an additional 5,579 shares during the last quarter. Finally, WCM Investment Management LLC increased its position in Ultragenyx Pharmaceutical by 49.1% during the first quarter. WCM Investment Management LLC now owns 202,213 shares of the biopharmaceutical company's stock worth $7,648,000 after buying an additional 66,604 shares during the last quarter. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.